Table 42

Design and Population Differences of Studies Comparing Fixed Epoetin Doses

Studylower doses1N eval.1higher doses1N eval.1baseline Hb categorymalignancy typecancer therapyEPO Tx durationiron use
Cazzola 1995 1,000
IU/day
2,000
A: 31

B: 29
5,000
IU/day
10,000
C: 31

D: 26
≤10 g/dLhematologicunspecified chemotherapy8 wksas needed
Glimelius 1998 2,000
IU
3X/wk
4110,000
IU
3X/wk
43>10-<12 g/dLsolid tumorsunspecified chemotherapy18 wksas needed
Johansson 2001 1,000
IU
3X/wk
905,000
IU
3X/wk
90≤10 g/dLsolidnot reported12 wksfixed
Olsson 2002 1,000
IU
3X/wk
905,000
IU
3X/wk
90≤10 g/dLsolidnot reported24 wksfixed
Sakai 2004 9,000
IU
1X/wk
18,000
A: 28

B: 29
36,000
IU
1X/wk
C: 29≤10 g/dLmixedunspecified chemotherapy12 wksfixed
1

Letters denoting study arms in Table 42 correspond to letters denoting study arms compared in Figures 31 and 32.

From: 3, Results

Cover of Comparative Effectiveness of Epoetin and Darbepoetin for Managing Anemia in Patients Undergoing Cancer Treatment
Comparative Effectiveness of Epoetin and Darbepoetin for Managing Anemia in Patients Undergoing Cancer Treatment [Internet].
Comparative Effectiveness Reviews, No. 3.
Seidenfeld J, Piper M, Bohlius J, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.